← Back to Search

Treatment for Tuberous Sclerosis

N/A
Recruiting
Research Sponsored by Boston Children's Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 months
Awards & highlights

Summary

This trial is to study and predict ASD and ID in patients with TSC, by looking at different brain activity and electrical biomarkers. They will also be collecting genetic material from patients and their families.

Eligible Conditions
  • Tuberous Sclerosis
  • Intellectual Disability
  • Autism

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in ADOS-2 scores at end of study
Fractional Precipitation
Change in SBIS-5 scores or Mullen Scales of Early Learning (MSEL) at end of study
+7 more

Find a Location

Who is running the clinical trial?

National Center for Advancing Translational Science (NCATS)NIH
99 Previous Clinical Trials
36,076 Total Patients Enrolled
Boston Children's HospitalLead Sponsor
778 Previous Clinical Trials
5,580,817 Total Patients Enrolled
5 Trials studying Tuberous Sclerosis
728 Patients Enrolled for Tuberous Sclerosis
National Institutes of Health (NIH)NIH
2,765 Previous Clinical Trials
8,133,316 Total Patients Enrolled
~21 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top